Literature DB >> 6860573

Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa.

D Vella Briffa, R A Eady, M P James, S Gatti, S S Bleehen.   

Abstract

Eight patients received PUVA for mastocytosis. Five women had typical adult-onset urticaria pigmentosa, without evidence of systemic disease. Another woman had suspected hepatic involvement while the remaining female had early-onset familial urticaria pigmentosa with morphologically atypical mast cells. The only male patient had cirrhosis with hepatic deposits of mast cells in addition to polycythaemia rubra vera. In all patients, except the man with systemic disease, there was reduced pruritus and wealing and partial to almost complete fading of the macules. The manifestations of urticaria pigmentosa recurred after treatment was discontinued. In both lesional and uninvolved skin there was no significant change in either the mean mast cell counts or mast cell ultrastructure after an average of twenty-seven PUVA exposures. In addition, PUVA did not cause a significant alteration in the histamine content of the skin. The beneficial effect of PUVA in urticaria pigmentosa therefore does not appear to be directly related to a change in mast cell numbers or morphology, or to the histamine concentration in the skin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6860573     DOI: 10.1111/j.1365-2133.1983.tb03994.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

1.  Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study.

Authors:  J H Olafsson; O Larkö; G Roupe; G Granerus; U Bengtsson
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

2.  Diffuse cutaneous mastocytosis with generalized bullae.

Authors:  Eui Hyung Lee; Mi Ri Kim; Tae Won Kang; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2010-02-28       Impact factor: 1.444

3.  Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes.

Authors:  B M Czarnetzki; T Rosenbach; G Kolde; P J Frosch
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

4.  Bullous mastocytosis treated with oral betamethasone therapy.

Authors:  Kaushal K Verma; Radhakrishna Bhat; Manoj K Singh
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

5.  Regulation of normal and neoplastic human mast cell development in mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

Review 6.  An approach to the patient with urticaria.

Authors:  S J Deacock
Journal:  Clin Exp Immunol       Date:  2008-08       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.